University of Arkansas

Bioventures, LLC

Mark S Smeltzer

Vladimir Pavlovich Zharov

Ekaterina Galanzha

Cesar M Compadre

Howard Hendrickson

Cassandra L Quave

Barry Hurlburt

Tammy M Rechtin

Sun Hee Moon

En Huang

Daniel Meeker

A method of non-invasively detecting and purging bacterial cells using a modified photoacoustic in vivo flow cytometer device is described herein. In particular, a method of detecting bacterial cells by analyzing photoacoustic pulses emitted in response to laser pulses from a pulsed laser source and/or selectively destroying the detected bacterial cells using a non-linear photothermal response induced by a high-energy laser pulse is described herein.

Device and method for in vivo photoacoustic diagnosis and photothermal purging of infected blood

Disclosed herein are linear lipopeptides having antimicrobial and antibiofilm activity. In one aspect of the invention the linear lipopeptide comprising a lipophilic terminus, an amine terminus, and a peptide interposed between the lipophilic terminus and the amine terminus or a salt thereof. The peptide may comprise any of SEQ ID Nos: 1-17 or a derivative thereof. Products comprising the lipopeptides and methods of using the same are also disclosed.

Linear lipopeptide paenipeptins and methods of using the same

The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.

Anti-biofilm compositions and methods for using

The present invention relates to inhibitors of Staphylococcus SarA protein function involved in the expression of staphylococcal virulence factors and the use of these inhibitors to treat and prevent staphylococcal infections in subjects. Particularly, the inhibitors act to interfere with the binding of the SarA protein to its binding site(s). The selection of specific inhibitors of the SarA protein is made possible as a result of the identification of the binding sites of SarA protein on at least a portion of the agr (accessory gene regulator) gene, a gene that like the sar (staphylococcal accessory regulator) gene, plays a role in the virulence of Staphylococcus. The present invention also is directed to a method of designing, synthesizing and identifying inhibitors of Sar A function and its role in the expression of staphylococcal virulence factors.

Inhibitors of staphylococcus SarA protein function involved in the expression of staphylococcal virulence factors and the use thereof in treating staphylococcal infections

The present invention provides a method of clinically differentiating the presence of Staphylococcus aureus in isolated samples, comprising the step of: analyzing the hybridization profile observed in Southern blots utilizing DNA probes for genes selected from the group consisting of the cna gene, the fnbA gene, the fnbB gene, the hlb gene, the cna-up gene, the pcp gene, the pcp12 gene and the pcp34 gene. Also provided is a kit for clinically differentiating the presence of Staphylococcus aureus in isolated samples, comprising: (1) restriction enzymes to digest genomic DNA contained in said samples; and (2) DNA probes for genes selected from the group consisting of the cna gene, the fnbA gene, the fnbB gene, the hlb gene, the cna-up gene, the pcp gene, the pcp12 gene and the pcp34 gene.

Growing community of inventors

Bryant, AR, United States of America

Mark S Smeltzer